Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer
- 1 January 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (1), 110-117
- https://doi.org/10.1200/jco.2006.08.3675
Abstract
Purpose: To evaluate the activity and safety of preoperative radiotherapy (RT) and concurrent capecitabine and oxaliplatin (XELOX-RT) plus four cycles of adjuvant XELOX in patients with rectal cancer. Patients and Methods: One hundred ten patients with T3/T4 or N+ rectal cancer were entered onto the trial in 11 investigator sites and received preoperative RT (50.4 Gy in 28 fractions). Capecitabine was administered concurrently at 1,650 mg/m2 on days 1 to 14 and 22 to 35, and oxaliplatin was administered at 50 mg/m2 on days 1, 8, 22, and 29. Surgery was scheduled 4 to 6 weeks after completion of XELOX-RT. Four cycles of adjuvant XELOX (capecitabine 1,000 mg/m2 bid on days 1 to 14; oxaliplatin 130 mg/m2 on day 1) were administered. The main end points were activity as assessed by the pathologic complete response (pCR) rate and the feasibility of postoperative XELOX chemotherapy. Results: After XELOX-RT, 103 of 104 eligible patients underwent surgery; pCR was achieved in 17 patients (16%), one patient had ypT0N1 disease, and 53 patients showed tumor regression of more than 50% of the tumor mass. R0 resections were achieved in 95% of patients, and sphincter preservation was accomplished in 77%. Full-dose preoperative XELOX-RT was administered in 96%. Grade 3 or 4 diarrhea occurred in 12% of patients. Postoperative complication occurred in 43% of patients. Sixty percent of patients received all four cycles of adjuvant XELOX, with sensory neuropathy (18%) and diarrhea (12%) being the main grade 3 or 4 toxicities. Conclusion: Preoperative XELOX-RT plus four cycles of adjuvant XELOX is an active and feasible treatment. This regimen is proposed for phase III evaluation comparing standard fluorouracil-based treatment with XELOX- based multimodality treatment.Keywords
This publication has 28 references indexed in Scilit:
- Postoperative Chemotherapy May Not Be Necessary for Patients With ypN0-Category After Neoadjuvant Chemoradiotherapy of Rectal CancerDiseases of the Colon & Rectum, 2006
- Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiationAnnals of Oncology, 2006
- The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?Annals of Oncology, 2006
- What Is the Best Way to Predict Disease-Free Survival After Preoperative Radiochemotherapy for Rectal Cancer Patients: Tumor Regression Grading, Nodal Status, or Circumferential Resection Margin Invasion?Journal of Clinical Oncology, 2006
- Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyAnnals of Oncology, 2005
- Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal CancerJournal of Clinical Oncology, 2005
- A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancerAnnals of Oncology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Oxaliplatin–5-Fluorouracil and Ionizing RadiationOncology, 2003
- Prolongation of the Disease-Free Interval in Surgically Treated Rectal CarcinomaNew England Journal of Medicine, 1985